IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4545
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$0
Eric A. Adams
InMed Pharmaceuticals Inc. researches and develops cannabinoid-based therapies. Lead product INM-755, a cannabinoidol topical cream, is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing InM-088, which is in preclinical studies for the. treatment of glaucoma and pain.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$INM InMed Pharmaceuticals Inc. | 30 | 35 | 25 | 6 | - | - | -88.1% | -75.5% | 28.5% | -126.2% | -200.3% | -35.1% | 0.0% | 17.0x | $0 | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
InMed Pharmaceuticals Inc. (INM) receives a "Avoid" rating with a composite score of 29.7/100. It ranks #4545 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Eric A. Adams
Chief Executive Officer
Labor Force
10
35
34
33
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for INM
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for INM.
View All RatingsHigh margin volatility — erratic forensic earnings quality
ROE proxy -88.1% (sector -2.5%)
GM 28% vs sector 43%, OM -126% vs sector 1%
Capital turnover N/A, R&D intensity 62.5%
Rev growth -35%, 6yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags InMed Pharmaceuticals Inc. with an Avoid rating, assigning a composite score of 29.7/100 and 1 out of 5 stars. Ranked #4545 of 7,333 stocks, INM falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
INM's quality score of 35/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -88.1% (sector avg: -2.5%), gross margins of 28.5% (sector avg: 42.5%), net margins of -200.3% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
INM registers a value score of just 25/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.26x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
InMed Pharmaceuticals Inc.'s investment score of 34/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -35.1% vs. a sector average of 5.9% and a return on assets of -75.5% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
InMed Pharmaceuticals Inc. is experiencing notably weak momentum with a score of just 6/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -35.1% year-over-year, while a beta of 1.03 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
INM's stability score of 33/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.03 and a debt-to-equity ratio of 17.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 44/100 for INM suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 17.00x), micro-cap liquidity risk. With a $0 market cap (micro-cap), InMed Pharmaceuticals Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
InMed Pharmaceuticals Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4545 of 7,333 overall (38th percentile). Key comparisons include ROE of -88.1% trailing the -2.5% sector median and operating margins of -126.2% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While INM currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (6) would have the largest impact on the composite score.
ROE 3454% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 33% BELOW SECTOR MEDIAN
Op. Margin 9885% BELOW SECTOR MEDIAN
AUDIT DATA AS OF DEC 31, 2025 (Q3 FY2025)
We rate InMed Pharmaceuticals Inc. (INM) as Avoid with a composite score of 29.7/100 at a current price of $0.89. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in quality (35th percentile) and investment (34th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (6th percentile) and value (25th percentile) tempers our overall conviction. We assign a No Moat rating (36/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
InMed Pharmaceuticals Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 29.7/100 places it at rank #4545 in our full 7,333-stock universe. At N/A in market capitalization, InMed Pharmaceuticals Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -35% combined with momentum at the 6th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 28% (-14.0pp vs sector) narrow to operating margins of -126% (-127.5pp vs sector) and net margins of -200.3%, yielding a gross-to-net conversion rate of -704%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.89, InMed Pharmaceuticals Inc. is trading at a premium to fundamental value. Our value factor score of 25/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 0.3x, P/S of 0.6x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
A conservative balance sheet (17% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 29.7/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -35% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -200.3% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (6th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
We assign a High uncertainty rating to InMed Pharmaceuticals Inc.. Key risk factors include current negative profitability (net margin -200.3%), below-average price stability (33th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -200.3%); below-average price stability (33th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 33th percentile and quality factor at the 35th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (17% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate InMed Pharmaceuticals Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-88.1%), negative profitability, weak asset returns (ROA -75.5%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — InMed Pharmaceuticals Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, InMed Pharmaceuticals Inc. receives a Avoid rating with a composite score of 29.7/100 (rank #4545 of 7,333). Our quantitative framework assigns a No Moat (36/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 27/100.
Our analysis does not support a constructive view on InMed Pharmaceuticals Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign InMed Pharmaceuticals Inc. a meaningful economic moat, scoring 36/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 11.7/20.
The strongest moat sources are growth durability (11.7/20) and financial resilience (8.9/20). Rev growth -35%, 6yr history. Interest coverage N/A. These pillars form the core of InMed Pharmaceuticals Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (2.5/20) and margin superiority (5.4/20). ROE proxy -88.1% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect InMed Pharmaceuticals Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include declining revenues (-35%) that pressure the earnings outlook. The margin cascade from 28% gross to -126% operating to -200.3% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 35th percentile.
The margin profile shows gross margins of 28%, operating margins of -126%, net margins of -200.3%. Return metrics include ROE of -88.1% and ROA of -75.5%. Relative to the Manufacturing sector, gross margins are 14.0 percentage points below the sector median of 43%, and ROE of -88.1% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 17%, revenue growth of -35%. The sector median D/E is 0%, putting InMed Pharmaceuticals Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Vancouver, British Columbia--(Newsfile Corp. - February 11, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of fiscal year 2026, which ended December 31, 2025.The Company's full financial statements and related MD&A for the second quarter ended...
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders held on December 17, 2025 (the "Meeting"), the matters put forward before shareholders for consideration and approval as set out in...
Shares of BlackBerry Limited (NYSE: BB) moved lower in pre-market trading following the release of third-quarter results. BlackBerry reported quarterly earnings of 1 cent per share which exceeded the Street's estimate of losses of 3 cents per share, according to Benzinga Pro. The company also said it sees fourth-quarter revenue of $150 million to $159 million. BlackBerry shares fell 5.4% to $3.88 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Infrared Cameras Holdings Inc (NASDAQ: MSAI) rose 213% to $8.20 in pre-market trading after falling over 61% on Wednesday. Mobile Global Esports Inc.(NASDAQ: MGAM) gained 53.4% to $0.4294 in pre-market trading after falling 4% on Wednesday. Mesoblast Limited (NASDAQ: MESO) shares gained 32.1% to $1.40 in pre-market trading. Mesoblast recently reported placement and accelerated non-renounceable entitlement offer to raise up to A$97 million. ParaZero Technologies Ltd. (NASDAQ: PRZO) shares surged 30.9% to $1.61 in pre-market trading. ParaZero shares jumped over 75% on Wednesday after the company announced ...
Global X’s investment chief, Jon Maier, reflects on the investment landscape for 2024, which is shaping up to be particularly interesting, thanks to AI-related stocks, cloud computing, cybersecurity, emerging markets, and small caps for potential growth. What Happened: Maier, who is associated with the $48 billion award-winning AI exchange-traded fund (ETF) provider Global X, has identified several promising sectors for investors in 2024, reported Business Insider. Among them, AI-related stocks, including Nvidia (NASDAQ:NVDA), cloud computing, and cybersecurity, stand out as “naturals that fit together.” Maier suggests investors consider the Global X Cloud Computing ETF (NASDAQ:CLOU) and the Global X Cybersecurity ETF (NASDAQ:BUG), or alternatives such as the First Trust Cloud Computing ETF (NASDAQ:SKYY) and the iShares Cybersecurity and Tech ETF (NYSE:IHAK). See Also: Shibu Inu Is At The Brink Of All-Time Highs, Will It Roar? When Analysts Expect A Historic Pop He also sees value in small ...Full story available on Benzinga.com
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. Nuvve Holding Corp. (NASDAQ: NVVE) shares climbed 88% to $0.2789 after falling 10% on Tuesday. Nuvve recently announced pricing of a $1 million underwritten public offering of roughly 7 million shares of common stock at a price to the public of $0.14 per share. BIO-key International, Inc. (NASDAQ: BKYI) surged 57% to $0.30. BIO-key International reported results for its third quarter ended Sept. 30, 2023. ReShape Lifesciences Inc. (NASDAQ: RSLS) gained 44.7% to $0.2976 after gaining over 6% on Tuesday. ReShape Lifesciences recently announced pricing of $3.0 million public offering. BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares climbed 37.6% to $3.2199 after announcing positive findings from an independent third party audit of the data integrity at TRANQUILITY II Phase 3 trial site. ParaZero Technologies Ltd. (NASDAQ: PRZO) gained 26% to $2.0350. Catalyst Biosciences, Inc. (NASDAQ: CBIO) climbed 18% to $0.5095. Scholar Rock Holding Corporation (NASDAQ: SRRK) gained 16.5% to $8.92. Jefferies upgraded Scholar Rock from Hold to Buy and announced a $20 price target. Stride, Inc. (NYSE: LRN) rose 16.4% to $51.81 after the company reported first-quarter results. OncoCyte Corporation (NASDAQ: OCX) gained 14.4% to $2.86. Urgent.ly Inc. (NASDAQ: ULY) surged 14% to $5.01. GameSquare Holdings, Inc. (NASDAQ: GAME) gained 13.1% to $2.07. Treasure Global Inc. (NASDAQ: TGL) rose 12.8% to $0.4501. PROG Holdings, Inc. (NYSE: PRG) rose 9.3% to $31.14 following upbeat quarterly results. LumiraDx Limited (NASDAQ: LMDX) gained 8.4% to $0.1680 after dipping around 44% on Tuesday. John Bean Technologies Corporation (NYSE: JBT) surged 8.1% to $104.00 after posting strong quarterly earnings. Sonendo, Inc. (NYSE: SONX) shares gained 8% to $0.2483 after falling over 23% on Tuesday. Sonendo recently announced preliminary revenue results for the third quarter. Crown ElectroKinetics Corp. (NASDAQ: CRKN) climbed 8% to $0.2700. Deutsche Bank Aktiengesellschaft (NYSE: DB) rose 6.6% to $10.72 after the company reported a year-over-year increase in third-quarter EPS and sales results. Deutsche Bank Aktiengesellschaft (NYSE: DB) gained 6.6% to $10.72 after the company reported a year-over-year increase in third-quarter EPS and sales results. The Gap, Inc. (NYSE: GPS) climbed 6.2% ...